Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ)
CNY13.44
+0.32 (+2.44%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
Concentrated Area, Yingbin Road 150078
Harbin, CN
Harbin, CN
CEO
Yi Guan
Website
kuihuayaoye.com
IPO
2014-12-30
ISIN CNE100001WT7
Description
Sunflower Pharmaceutical Group Co., Ltd. is a Chinese enterprise dedicated to the comprehensive process of traditional Chinese medicine (TCM), covering everything from research and development to production and market distribution within China. The company's product range also extends to include chemical, biological, and health-focused pharmaceuticals. These diverse medications address a broad spectrum of medical needs, providing solutions in areas such as pediatrics, gynecology, digestive system ailments, respiratory issues including the common cold, conditions related to rheumatism and bone health, and cardiovascular and cerebrovascular disorders. The company's goods are sold under its established brands, "Sunflower" and "Little Sunflower." With its headquarters located in Harbin, China, Sunflower Pharmaceutical Group was founded in 2005.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY13.44
+0.32 (+2.44%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.31
Float Shares
210.63M
Free Float %
36.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.19% | +1.87% | -0.15% | -6.77% | -11.14% | -11.44% | -18.10% | -51.43% | -16.42% | -21.44% | -0.53% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
13.44
DCF (Unlevered)
15.58
+15.9%
DCF (Levered)
19.39
+44.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.07
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-31.4% Q1'26: +27.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-152.4% Q1'26: +90.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+20.6% Q1'26: +6.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-9.2% Q1'26: +16.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-14.2% Q1'26: +30.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-2.55× Q1'26: 0.19× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.03B
est: 3.55B (-14.5%)
|
3.36B
est: 3.20B (+5.0%)
|
3.86B
est: 3.85B (+0.1%)
|
4.47B
est: 4.55B (-1.7%)
|
4.37B
est: 5.24B (-16.6%)
|
3.46B
est: 6.00B (-42.3%)
|
4.46B
est: 7.18B (-37.9%)
|
5.09B
est: 5.05B (+0.9%)
|
5.70B
est: 5.90B (-3.3%)
|
3.38B
est: 6.34B (-46.7%)
|
2.32B
est: 7.13B (-67.5%)
|
8.03B
8.03B – 8.03B
+12.6% YoY
|
| EBITDA |
424.70M
est: 794.66M (-46.6%)
|
481.05M
est: 717.16M (-32.9%)
|
648.54M
est: 862.41M (-24.8%)
|
779.91M
est: 1.02B (-23.4%)
|
851.72M
est: 1.17B (-27.5%)
|
811.07M
est: 1.34B (-39.7%)
|
935.80M
est: 1.61B (-41.8%)
|
1.29B
est: 1.13B (+13.6%)
|
1.36B
est: 1.32B (+2.9%)
|
625.66M
est: 1.10B (-43.1%)
|
-43.71M
est: 1.24B (-103.5%)
|
1.39B
1.39B – 1.39B
+12.6% YoY
|
| EBIT |
333.35M
est: 643.26M (-48.2%)
|
346.38M
est: 580.53M (-40.3%)
|
504.22M
est: 698.10M (-27.8%)
|
635.65M
est: 824.47M (-22.9%)
|
702.19M
est: 950.57M (-26.1%)
|
661.92M
est: 1.09B (-39.2%)
|
771.33M
est: 1.30B (-40.7%)
|
1.02B
est: 915.58M (+11.7%)
|
1.18B
est: 1.07B (+10.7%)
|
452.83M
est: 791.02M (-42.8%)
|
-212.03M
est: 889.71M (-123.8%)
|
1.00B
1.00B – 1.00B
+12.6% YoY
|
| Net Income |
306.60M
est: 398.32M (-23.0%)
|
303.02M
est: 322.17M (-5.9%)
|
424.00M
est: 410.04M (+3.4%)
|
563.28M
est: 571.12M (-1.4%)
|
565.42M
est: 720.50M (-21.5%)
|
584.45M
est: 902.08M (-35.2%)
|
704.74M
est: 960.66M (-26.6%)
|
867.22M
est: 866.94M (+0.0%)
|
1.12B
est: 1.14B (-2.0%)
|
492.05M
est: 1.21B (-59.4%)
|
-257.83M
est: 1.34B (-119.3%)
|
1.48B
1.48B – 1.48B
+11.0% YoY
|
| SGA |
1.29B
est: 1.15B (+12.6%)
|
1.53B
est: 1.04B (+47.5%)
|
1.61B
est: 1.24B (+29.1%)
|
1.80B
est: 1.47B (+22.6%)
|
1.64B
est: 1.69B (-3.0%)
|
1.18B
est: 1.94B (-39.0%)
|
1.64B
est: 2.32B (-29.4%)
|
1.74B
est: 1.63B (+6.4%)
|
1.82B
est: 1.91B (-4.4%)
|
831.53M
est: 2.16B (-61.6%)
|
1.00B
est: 2.43B (-58.9%)
|
2.74B
2.74B – 2.74B
+12.6% YoY
|
| EPS |
0.53
est: 0.68 (-22.8%)
|
0.52
est: 0.55 (-5.5%)
|
0.73
est: 0.70 (+4.3%)
|
0.96
est: 0.98 (-1.5%)
|
0.97
est: 1.23 (-21.1%)
|
1.00
est: 1.54 (-35.1%)
|
1.21
est: 1.64 (-26.2%)
|
1.48
est: 1.48 (+0.0%)
|
1.92
est: 1.95 (-1.5%)
|
0.84
est: 2.07 (-59.4%)
|
-0.44
est: 2.28 (-119.3%)
|
2.53
2.53 – 2.53
+11.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
438.01M
OE per share TTM
0.66
Owner's Yield
5.77%
Maintenance CapEx ratio
33.05%
Maint CapEx / Avg PPE
35.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 19 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 53.4K | 0.65% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 283.5K | 0.06% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 27.0K | 0.46% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 102.4K | 0.39% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 86.0K | 0.29% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.0K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 20.2K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 996.6K | 0.06% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 68.3K | 0.28% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.05M | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-37.0K
Shares Outstanding
584.00M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chao Guo | Deputy General Manager | — | male |
| Chunhong Wu | Financial Manager | — | female |
| Guangguang Zhou | Board Secretary | — | male |
| Li Chen | Accounting Supervisor | — | — |
| Liang Chen | Deputy General Manager | — | male |
| Xin Ma | Deputy General Manager | — | male |
| Yang Hai | Deputy General Manager | — | male |
| Yang Yang | Deputy GM & Non-Independent Director | — | male |
| Yi Guan | GM & Non-Independent Director | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002737.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
